No licensed seller offers tirzepatide for sale without a prescription. Every tirzepatide product the FDA has approved is a prescription-only injection sold under one of two brand names, Mounjaro or Zepbound, so any storefront that will take your card without a prescriber involved is either an unlicensed research-peptide vendor or an outright scam.
That matters because "tirzepatide for sale" is not a pharmacy query. People typing it are usually past the prescription conversation, looking at grey-market listings priced at a fraction of the brand. This page covers the routes that actually exist, what each costs with a source and a date, and what the law says about vials stamped "research use only."
The honest caveat: compounded tirzepatide is the same active molecule as the branded drug but is not FDA-approved. If your insurance covers a branded GLP-1, that route is cheaper and we earn nothing from it.
See if you qualify →Partner link: we may earn a commission at no extra cost to you. Prices checked 24 August 2026.
The four routes that actually exist
| Route | Prescription required | What you receive | Cost per month | Legal status |
|---|---|---|---|---|
| LillyDirect self-pay | Yes | Zepbound vials or KwikPen from the manufacturer | $299 to $699 | Legal, FDA-approved |
| Retail pharmacy on insurance | Yes | Mounjaro or Zepbound pens | $25 with a savings card if covered | Legal, FDA-approved |
| Telehealth to a brand script | Yes | Same approved product, plus a visit fee | Drug cost plus visit fee | Legal if the prescriber is state-licensed |
| Personalised 503A compounding | Yes | Compounded, not FDA-approved | Varies by pharmacy | Narrow and contested since 2025 |
| Research-peptide vendors | No | Unapproved powder, unknown contents | Advertised below brand | Unapproved new drug, illegal to sell |
Only the top three are routes a pharmacist would recognise. The fourth has narrowed sharply. The fifth is not a market so much as an enforcement target.
Why the prescription is not a formality you can route around
Tirzepatide carries a boxed warning for thyroid C-cell tumours and requires structured dose titration. It is not sold over the counter anywhere in the United States, and there is no generic: Lilly holds exclusivity on both brands. On DailyMed, every tirzepatide listing is the same dosage form, "injection, solution."
If a site sells you tirzepatide without asking who is prescribing it, the missing prescription is not the only rule being skipped, and the ones you cannot see govern sterility and dose accuracy.
What tirzepatide costs when you pay cash legally
Lilly sells Zepbound directly to self-pay patients through LillyDirect. These are the prices published on Lilly's own savings page as of August 2026:
| Dose | Self-pay price, KwikPen or vial | Regular price without the refill offer |
|---|---|---|
| 2.5 mg | $299 | $299 |
| 5 mg | $399 | $399 |
| 7.5 mg | $449 | $499 |
| 10 mg | $449 | $699 |
| 12.5 mg | $449 | $699 |
| 15 mg | $449 | $699 |
The $449 tier at 7.5 mg and above is a purchase offer, not a standing price. You keep it only by completing each refill within 45 days of the previous one. Miss the window and you pay the right-hand column.
With commercial insurance that covers the drug, the Zepbound savings card can bring a one to three month fill of the single-dose pen to as little as $25, capped at $1,300 of savings per calendar year. For type 2 diabetes, the Mounjaro savings card works the same way at $25 with coverage, or $499 a month if your plan excludes it. Our tirzepatide cost breakdown sets these against pharmacy cash prices.
Compounded tirzepatide is not the workaround it was in 2023
The shortage is over, and with it the legal basis for mass compounding. FDA added tirzepatide injection to the shortage list on 15 December 2022, removed it on 2 October 2024, and after a court-ordered reevaluation reaffirmed on 19 December 2024 that the shortage was resolved. That memo gave 503A pharmacies 60 calendar days of enforcement discretion and 503B outsourcing facilities until 19 March 2025.
Both deadlines passed more than a year ago. What survives is narrower: a 503A pharmacy compounding for an identified individual patient whose prescriber documents a clinical need the approved product cannot meet. That is a real lane, but not a subscription product, and FDA has kept closing doors. On 1 May 2026 the agency proposed not to include semaglutide, tirzepatide, or liraglutide on the 503B bulks list, finding no clinical need for outsourcing facilities to compound them from bulk substance. The comment period ran to 30 July 2026.
If a telehealth site is still selling a standing monthly compounded subscription, read our pages on compounded tirzepatide and tirzepatide compounding pharmacies first, and ask which specific clinical need is being documented for you.
What "research use only" actually means legally
It means nothing about the product and everything about the seller's legal exposure.
FDA has repeatedly held that the disclaimer does not control. In warning letters dated 31 March 2026 to Gram Peptides, Prime Sciences, and Mile High Compounds, the agency wrote: "Despite statements on your product labeling marketing your products for 'Research Use Only,' and 'not intended for human consumption, medical use, or veterinary use,' evidence obtained from your website establishes that your products are intended to be drugs for human use."
What established intended use was the marketing around the vial: weight-loss and glucose claims, dosing language, and bacteriostatic water sold alongside a product that requires reconstitution. FDA declared the bacteriostatic water a drug too, reasoning that selling them together shows they are meant to be injected. All of it became an unapproved new drug under section 505(a), with seizure and injunction named as remedies.
FDA's consumer page on unapproved GLP-1s carries a section headed "Versions sold falsely for research purposes or not for human consumption." As of 31 May 2026 the agency had logged 990 adverse event reports tied to compounded semaglutide and more than 730 tied to compounded tirzepatide, and notes that state-licensed pharmacies are not required to report at all.
The disclaimer is a shield the seller holds. It is not one you stand behind.
How to read a scam listing
The strongest published evidence on what these sites ship is a 2024 study in the Journal of Medical Internet Research, which surveyed 1,080 search results for prescription-free semaglutide, identified 59 illegal online pharmacy domains, and made six test purchases:
- Three of six orders never arrived. Straight non-delivery fraud.
- All three delivered vials were assessed as probable substandard or falsified products, failing 59% to 63% of visual packaging criteria.
- Measured purity was 7.7% to 14.37% against a 99% label claim.
- Semaglutide content exceeded the labelled amount by 28.56% to 38.69%.
- Endotoxin was detected in every sample, at 2.1645 to 8.9511 EU/mg.
That is semaglutide, not tirzepatide, but it is the same supply chain and the same storefronts. Read the purity and content numbers together: those vials were both underpure and overfilled, the worst combination for anyone drawing a dose by units.
FDA's own warning-sign list is worth memorising: prices too good to be true, no screening by a licensed prescriber, nobody available to answer questions after delivery, spelling errors on the label, a pharmacy address that does not check out, and packaging that differs from what was pictured. Injectable GLP-1s need refrigeration, so a parcel arriving warm is a discard, not a judgement call.
Why price alone signals nothing
Buyers read a low price as evidence of a direct source and a high price as evidence of quality. Neither inference holds.
A vial containing 40% of its labelled peptide costs the seller 40% as much to fill, and nothing would reveal that to you. Nor does anything stop a scam listing from pricing at $400 a month to look legitimate. Price reflects what the seller thinks you will pay, and says nothing about identity, purity, sterility, or endotoxin load.
The only thing that does carry information is batch-specific third-party analysis, and even that can be forged. Treat the following as a minimum, not a guarantee of safety:
- Batch-specific, not product-generic. It must name the lot number printed on the vial in your hand. A PDF covering "tirzepatide" generally is marketing.
- Identity and purity separately. Mass spectrometry confirms the molecule; HPLC quantifies how much of the sample is that molecule. A high purity figure on the wrong molecule is meaningless.
- Sterility and endotoxin, not just purity. A sample can be 99% pure and still carry an endotoxin load no pharmacy would release. Most vendor certificates omit it.
- Verify with the lab, not the vendor. A certificate hosted only by the seller is verified by nobody.
- Check the date. A certificate from a two-year-old batch says nothing about the vial shipping today.
We recommend no grey-market vendor, and nothing above makes an unapproved injectable safe. If cost is the driver, compare the cheapest legitimate routes and buying tirzepatide online first.
There is no oral tirzepatide
No tablet, capsule, sublingual troche, or nasal spray containing tirzepatide has ever been approved anywhere. Every approved tirzepatide product is a subcutaneous injection, and the formulations sold online as "tirzepatide pills" were never in the trials that supported Mounjaro or Zepbound.
The confusion is understandable, because an oral GLP-1 pill for obesity does now exist. Foundayo (orforglipron) was approved in 2026 as a once-daily tablet. It is a small-molecule GLP-1 receptor agonist, a different compound entirely, not a pill version of tirzepatide. Anyone selling "tirzepatide tablets" is selling something that does not exist as an approved product.
Frequently Asked Questions
Can you buy tirzepatide without a prescription?
Not legally, and not from anyone accountable if something goes wrong. FDA has issued warning letters treating prescription-free sales as introducing an unapproved new drug into commerce.
Is tirzepatide for sale online legal if the site is based overseas?
No. FDA's position is that "in most circumstances, it is illegal for individuals to import drugs or devices into the U.S. for personal use." The narrow exception covers serious conditions with no domestic treatment available, which does not apply when the approved product is in stock here.
Why is grey-market tirzepatide so much cheaper than the brand?
It skips clinical trials, sterile fill-finish under CGMP, batch release testing, cold chain, and liability. The JMIR test purchases found vials measuring 7.7% to 14.37% pure against a 99% claim, which is where the savings come from.
Are tirzepatide pills or tablets for sale real?
No. Every tirzepatide entry on DailyMed is an injection. Products advertised as tirzepatide pills, drops, or sublingual tablets have not been evaluated by FDA for safety or effectiveness in those forms.
What should a tirzepatide certificate of analysis show?
The lot number, identity by mass spectrometry, purity by HPLC, sterility, endotoxin testing, and a test date within the life of that batch. Verify it with the issuing laboratory, not a seller-hosted PDF. It covers one batch; it is not a safety clearance.
Can a compounding pharmacy still sell me tirzepatide in 2026?
Only narrowly: a 503A pharmacy compounding for you individually, where your prescriber documents a clinical need the approved product cannot meet. Shortage-era enforcement discretion ended in early 2025, and FDA proposed in May 2026 to keep tirzepatide off the 503B bulks list.
What is the cheapest legitimate way to get tirzepatide?
If insurance covers it, a savings card at $25 a fill. If not, LillyDirect self-pay at $299 a month for the 2.5 mg starting dose, rising to $449 for maintenance doses when refills stay inside the 45-day window. Our where to buy tirzepatide page compares every route side by side.
Sources
- FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss — U.S. Food and Drug Administration
- Resolution of Tirzepatide Injection Product Shortage and Supply Status, 19 December 2024 — U.S. Food and Drug Administration
- FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List — U.S. Food and Drug Administration
- List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B; Extension of Comment Period — Federal Register
- Warning Letter: Gram Peptides, 31 March 2026 — U.S. Food and Drug Administration
- Warning Letter: Prime Sciences, 31 March 2026 — U.S. Food and Drug Administration
- Personal Importation — U.S. Food and Drug Administration
- Multifactor Quality and Safety Analysis of Semaglutide Products Sold by Online Sellers Without a Prescription — Journal of Medical Internet Research (2024;26:e65440)
- Zepbound Savings and Insurance Options — Eli Lilly and Company
- Mounjaro Savings and Resources — Eli Lilly and Company
- The Risks of Counterfeit and Compounded Medicine — Eli Lilly and Company
- Zepbound (tirzepatide) injection, solution — DailyMed
- Foundayo (orforglipron) tablet, film coated — DailyMed
